JNJ (JNJ) Makes Investors Think Following Q2 Beat as FY11 Outlook Maintained

Johnson & Johnson (NYSE: JNJ) is trading modestly higher this morning, as the company bested second-quarter expectations, but simply reaffirmed its outlook.

Global sales in the quarter increased 8.3 percent, or 5.7 percent on a constant-currency basis, to $16.597 billion. The number beat Street views calling for $16.22 billion.

Net income in the quarter grew 4.9 percent to $3.548 billion, or $1.28 per share, topping views calling for earnings of $1.23 per share.

Net margin consolidated somewhat in the quarter, from 22.1 percent to 21.4 percent.

Johnson & Johnson's OTC/Nutritionals segment recorded the largest relative loss in the quarter, dropping 11.5 percent to $1.083 billion. Skin Care made the biggest relative gain, jumping 5.3 percent to $929 million.

"Our recently launched pharmaceutical products continued to achieve strong growth and contributed to our solid second quarter results," commented CEO William C. Weldon. "We received several new product approvals across our businesses which will benefit patients around the world and drive future growth."

Fiscal 2011 guidance was maintained, calling for earnings of $4.90 to $5.00 per share which compares to the consensus of $4.95.

Johnson & Johnson shares are up about 0.2 percent pre-market Tuesday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
• Deutsche Bank monitors UK auto sales as Chinese exports grow